Back to top

Why the Earnings Streak Will Continue for Vertex Pharmaceuticals (VRTX)
October 10, 2017

Read MoreHide Full Article

Looking for a stock that might be in a good position to beat earnings at its next report? Consider Vertex Pharmaceuticals Incorporated (VRTX - Free Report) , a firm in the Medical - Biomedical and Genetics industry, which could be a great candidate for another beat.

This company has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. In fact, in these reports, VRTX has beaten estimates by at least 10% in both cases, suggesting it has a nice short-term history of crushing expectations.

Earnings in Focus

Two quarters ago, VRTX was expected to post 29 cents per share, while it actually produced 41 cents per share, a beat of 41.4%. Meanwhile, for the most recent quarter, the company looked to deliver 35 cents per share, when it actually saw 39 cents per share instead, representing a 11.4% positive surprise.

Thanks in part to this history, recent estimates have been moving higher for Vertex Pharmaceuticals. In fact, the Earnings ESP for VRTX is positive, which is a great sign of a coming beat.

After all, the Zacks Earnings ESP compares the most accurate estimate to the broad consensus, looking to find stocks that have seen big revisions as of late, suggesting that analysts have recently become more bullish on the company’s earnings prospects. This is the case for VRTX, as the firm currently has a Zacks Earnings ESP of +2.56%, so another beat could be around the corner.

This is particularly true when you consider that VRTX has a great Zacks Rank #1 (Strong Buy), which can be a harbinger of outperformance and a signal for a strong earnings profile. You can see the complete list of today’s Zacks #1 Rank stocks here.

When you add this solid Zacks Rank to a positive Earnings ESP, a positive earnings surprise happens nearly 70% of the time, so it seems pretty likely that VRTX could see another beat at its next report, especially if recent trends are any guide.

Today's Stocks from Zacks' Hottest Strategies

It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.

And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation. See Them Free>>

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Vertex Pharmaceuticals Incorporated (VRTX) - free report >>

More from Zacks Tale of the Tape

You May Like